Relative to the distribution of opioid antagonists at correctional facilities
Summary
House Bill 4123 would require correctional facilities in Massachusetts, including county correctional facilities, state prisons, jails, and houses of correction, to provide an incarcerated person with two doses of an opioid antagonist at the time of direct release. The bill defines “opioid antagonist” to include naloxone and any other FDA-approved drug used to reverse opioid overdoses, and it specifies that the distribution must be carried out by a Department-approved pharmacist or designee.
The measure is aimed at reducing overdose deaths during the high-risk period immediately after release from incarceration. By ensuring access to overdose-reversal medication upon release, the bill seeks to create a standard statewide practice for correctional institutions and to connect people leaving custody with a life-saving intervention that can be used by the individual or others in the event of an overdose.
Impact
The bill would amend Chapter 126 of the Massachusetts General Laws by adding a new section governing opioid antagonist distribution at correctional facilities. It would impose an affirmative duty on correctional institutions to provide two doses of naloxone or another approved opioid antagonist to eligible individuals upon direct release, thereby creating a new statutory requirement for the Department of Correction, county facilities, jails, and houses of correction. The practical effect would be to expand post-release overdose prevention measures and likely require facilities to establish procurement, dispensing, and release procedures for these medications.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the overall sentiment appears supportive and public-safety oriented. The proposal is framed as a harm-reduction and overdose-prevention measure, with no documented opposition in the provided materials. Its sponsors are from different districts, suggesting a bipartisan or at least cross-regional interest in addressing the opioid crisis among people leaving custody.
Contention
No specific points of contention are documented in the provided committee or voting history. Potential areas of debate, if the bill advances, could include the cost and logistics of supplying two doses per release, the role of pharmacists or designees in correctional settings, and whether the mandate should apply uniformly to all facilities. Another possible issue is whether the requirement should be paired with additional discharge planning, treatment referrals, or training for released individuals and staff.